Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
AssigneeNovartis AG
InventorsCarolyn Ann Foster, Peter C. Hiestand, Paul William Glue
Life of this patent
Estimating the term…
Abstract
Disclosed are pharmaceutical combinations comprising at least one S1P receptor agonist, as well as a method for treating demyelinating diseases, e.g. multiple sclerosis or disorders associated therewith or Guillain-Barré syndrome, comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a) an S1P receptor agonist, and b) at least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease.
Claims16
A pharmaceutical combination comprising:
- a) a sphingosine-1-phosphate (S1P) receptor agonist, and
- b) at least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease.
A pharmaceutical composition for treating, alleviating or delaying progression of optic neuritis comprising an S1P receptor agonist together with one or more pharmaceutically acceptable diluents or carriers therefor.
A method for treating, alleviating or delaying progression of the symptoms of a demyelinating disease comprising co-administration of a therapeutically effective amount of a) an S1P receptor agonist, and b) at least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease.
A method for treating, alleviating or delaying progression of optic neuritis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of an S1P receptor agonist.
Use of a) a sphingosine-1-phosphate (S1P) receptor agonist, and b) at least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease, for the preparation of a pharmaceutical combination for treating, alleviating or delaying progression of the symptoms of a demyelinating disease.
Use of an S1P receptor agonist for the preparation of a medicament for treating, alleviating or delaying the progression of optic neuritis.
Dependencies are inferred from the claim text.